Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c 2.4 mg Once-weekly	Novo Nordisk	Ongoing	Semaglutide	3	NN9536-7752	King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh) ,King Abdulaziz Hospital NG (Al Ahsa), King Abdulaziz Medical City NG (Jeddah) ,King Faisal Specialist Hospital and Research Center (Riyadh) , King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II (RAPIDe-2)	Pharvaris Netherlands B.V.	Ongoing	Deucrictibant	2/3	PHA022121-C303	King Faisal Specialist Hospital and Research Center (Riyadh)
A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants with Propionic Acidemia	Moderna	Ongoing	mRNA-3927	1/2	mRNA-3927-P101	King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh)
Real-World Evidence non-interventional prospective study for the effectiveness, tolerability and adherence of Asciminib after two previous TKIs in Patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) in Saudi Arabia. (ASC4REAL)	Novartis	Ongoing	Scemblix (Asciminib/ ABL001)	4	CABL001ASA	King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Medical City NG (Jeddah),King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh)
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER™-ON)	Boehringer Ingelheim	Ongoing	BI 1015550	3	1305-0031	King Abdulaziz Medical City NG (Riyadh)
Netupitant and palonosetron fixed-dose combination versus 5-HT3 receptor antagonists in preventing chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: A randomized, open-label, phase IV trial	PI initiatied	Ongoing	Netupitant and palonosetron, Granisetron transdermal patch, Ondansetron	4	24-1205	King Abdullah Medical City (Makkah)
A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT)	Astrazeneca	Ongoing	Ultomiris (Ravulizumab)	4	ALX-NMO-50	King Khalid University Hospital (Riyadh),King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Medical City NG (Riyadh),King Fahad Medical City (Riyadh)
A PHASE III, PROSPECTIVE OPEN-LABEL, MULTI-CENTER SINGLE ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) PROFILE OF INTRAVENOUS HUMAN NORMAL IMMUNOGLOBULIN (IgG) IN PRIMARY IMMUNODEFICIENCY DISEASE (PID) PATIENTS	Celgene Corporation	Ongoing	Golcadomide,BMS-986369 / CC-99282	3	SKP-LIV_PID_III_2023	King Abdulaziz University Hospital (Jeddah), King Fahad Hospital (Jeddah) ,Al-Aziziyah Maternity and Children's Hospital , King Abdulaziz Medical City NG (Jeddah) , King Abdulaziz Medical City NG (Riyadh)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)	Celgene Corporation	Ongoing	Golcadomide,BMS-986369 / CC-99282	3	CA0731020	King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam), King Abdullah Medical Complex (Jeddah)
INTERnational STudy Evaluating Lupus Outcomes after Anifrolumab Real-World Use (INTERSTELLAR): Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice	King Faisal Specialist Hospital and Research Center (Riyadh)	Ongoing	Semaglutide	3	2241130	King Faisal Specialist Hospital and Research Center (Riyadh)